Related Experiment Video
Updated: Sep 21, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry
Masahiro Esato1, Yoshimori An2, Hisashi Ogawa2
1Department of Cardiology, Heart Rhythm Section, Ogaki Tokushukai Hospital, Gifu, Japan.
Background:
The risk for thromboembolism depending on the different age subgroups in patients with atrial fibrillation (AF) has not been fully elucidated.
Methods:
The Fushimi AF Registry is a community-based prospective survey of patients with AF in Fushimi-ku, Kyoto. Follow-up data were available for 4,466 patients by the end of 2019. Clinical determinants and the description of variables which interact and lead to the incidence of thromboembolism (the composite of ischemic stroke and systemic embolism [SE]) were identified in overall population and in age subgroups (≤64, 65-74, and ≥ 75 years).
Results:
A total of 314 patients developed thromboembolism during the median follow-up of 1,610 days (1.56 per 100 person-years). The independent determinants were age advance (per 10 years, hazard ratio [HR]: 1.51, 95% confidence interval [CI]: 1.22-1.86, P < 0.001), low body weight (HR: 1.91, 95% CI: 1.35-2.70, P < 0.001), history of stroke or SE (HR: 2.06, 95% CI: 1.54-2.76, P < 0.001), chronic kidney disease (HR: 1.34, 95% CI: 1.01-1.78, P = 0.043), and left atrial enlargement (HR: 1.57, 95% CI: 1.18-2.10, P = 0.0021). With regard to the age subgroup analysis, diabetes mellitus (P = 0.043), vascular disease (P = 0.005), male sex (P = 0.022), and sustained AF (P = 0.014) indicated significantly relevant interactions between the age subgroups and thromboembolism.
Conclusion:
The risk and the impact of baseline characteristics on thromboembolism in patients with AF varied depending on the age subgroups.
More Related Videos
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Aortic Regurgitation III: Medical Management
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis III: Management

